DLBCL

In an interview with Targeted Oncology, Nilanjan Ghosh, MD, discussed the current challenges in using CAR T-cell therapy as treatment of patients with DLBCL and considers the next steps for this research.

Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.

Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.

Two immune systems conditions, hypogammaglobulinemia and hypocomplementemia, may be predictive of adverse outcomes in patients with diffuse large B-cell lymphoma, according to a published study.

Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.

The first CD19/22-directed dual targeting CAR T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the remaining unmet needs that exist in the treatment landscape of diffuse large B-cell lymphoma.